Both in the context of exclusively dietary interventions and after bariatric surgery or treatment with GLP(glucagon-like peptide)-1 analogs, there is not only a reduction in weight, but also a loss of muscle mass to varying degrees. A differentiated clinical examination shows that this loss does not necessarily equate to a functional deterioration.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- From symptom to diagnosis
Abdominal pain – external hernias
- Mechanisms, evidence and therapeutic consequences
GLP-1 receptor agonists in cardiology
- MASLD/MASH
Drug therapy options on the rise: spectacular evidence
- New ways of neuroregeneration
CRISPR and artificial intelligence
- Asbestos victims
Federal Council has decided to amend the UVG
- Music as a cure for cancer?
Music therapy in Swiss oncology
- Clinical significance, pathophysiology, diagnosis and management
Frailty in COPD
- Bladder infections and urinary tract infections